1,126 results on '"Denkert, C."'
Search Results
2. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
6. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
7. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
8. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
9. Endoscopic full-thickness resection (eFTR) for the treatment of neuroendocrine tumors of the rectum: The new standard procedure?
10. Recurrence rate after (f)EMR of colon adenomas≥2 cm: A retrospective single-center analysis
11. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
12. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
13. Beurteilung der Schwingfestigkeit von Schrauben großer Durchmesser im Maschinenund Anlagenbau unter Berücksichtigung von Herstellungs- und Randschichteinflüssen
14. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
15. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆
16. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
17. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
18. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
19. EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
20. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
21. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
22. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
23. Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
24. Endoskopische Vollwandresektion (eFTR) zur Behandlung von neuroendokrinen Tumoren des Rektums: Das neue Standard-Verfahren?
25. Rezidivrate nach (f)EMR von Colonadenomen≥2 cm: Eine retrospektive Single Center Analyse
26. Endoskopische Vollwandresektion (eFTR) allein vs. Hybrid-eFTR zur Behandlung neoplastischer kolorektaler Läsionen: eine retrospektive Vergleichsstudie
27. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer
28. A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer
29. Update der S3-Leitlinie Mammakarzinom: Was gibt es Neues für Pathologen?
30. Aktuelle Aspekte der Diagnostik von Ovarialtumoren
31. Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom: Ein prognostischer Marker für die histologische Diagnostik
32. 99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)
33. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)
34. 129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort
35. 167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort
36. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
37. SA 3.2 Tumor microenvironment in early breast cancer
38. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
39. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
40. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast
41. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
42. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
43. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
44. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
45. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
46. 106P Ultra low-coverage whole genome sequencing for precision oncology in solid tumors
47. HRD-Testung und BRCA1/2-Keimbahntestung in der klinischen Routine bei Patientinnen mit primärem Ovarialkarzinom
48. Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry
49. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial
50. Multigentests zur Risikoabschätzung beim frühen Mammakarzinom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.